Tony received his Ph.D. from Purdue University under the tutelage of Professor Eiichi Negishi (2010 Nobel Prize winner). Prior to founding Tyligand, he has served as the Senior Research Fellow of Small Molecule Design and Development of Eli Lilly, the founding Managing Director of Lilly China R&D Center, and the Vice President of Eli Lilly Global External R&D for Asia. He has also served as Chairman of BayHelix Group and adjunct professor of several leading universities.

Dr. Zhong received Ph.D. in Medicinal Chemistry from Northwestern (Prof. Richard Silverman) and received postdoctoral training fellow at Caltech and Harvard. He has over 25 years experience in cancer research, leaving a long track record of drug hunting success at Eli Lilly, CrownBio, Immune Sensor, and Gan & Lee. Over 10 candidates to his credit have entered into trials, including Bozitinib/Vebreltinib, which was named after him and is the most selective kinase inhibitor known so far and is pending approval in US and China.

Zhong-Yin Zhang is the distinguished Professor of Medicinal Chemistry, Robert C. and Charlotte P. Anderson Chair in Pharmacology, and Head of the Department of Medicinal Chemistry and Molecular Pharmacology. He also serves as the Director of the Institute for Drug Discovery at Purdue University. His research spans the disciplines of chemistry and biology with an emphasis on PTP structure and function, signaling mechanism, and development of PTP inhibitors as novel therapeutics.

Jing Cindy Li has extensive experience in the clinical development of innovative drugs. She has previously worked at Sanofi, HUTCHMED, and Transcenta, where she and her team successfully brought several drug to market in China and into global development. Her work experience covers the full life cycle of drug clinical development in support of making innovative medicines available to patients globally.